Heyholder

This is an amended filing · View original →

‹ Activism Filings

KYUNG NAM PHARM.CO.,LTD. Q3 revenue KRW 20.7 billion, operating loss KRW 1.3 billion; revenue up 46.2% from a year earlier

KYUNG NAM PHARM.CO.,LTD.· Periodic ReportAmended

AI summary · Not investment advice

In Q3, the company sold KRW 20.7 billion worth and lost KRW 1.3 billion from its main business; sales rose 46.2% from a year earlier and 16.3% from the prior quarter.

Operating profit · 3 months

KRW -1.3 billion

Key facts

Revenue (3 months)
KRW 20.7 billion
Net income (3 months)
KRW -2.9 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 14.2 billion
Revenue (year to date)
KRW 54.6 billion
Operating profit (prior-year 3 months)
KRW -1.1 billion
Operating profit (year to date)
KRW -1.1 billion
Net income (prior-year 3 months)
KRW -4.7 billion
Net income (year to date)
KRW -7.2 billion

Commentary

AI commentary · Not investment advice

What happened

Kyungnam Pharm reported its consolidated results for the third quarter. Sales for the latest 3 months were KRW 20.71 billion. That is 46.2% more than the same period a year earlier and 16.3% more than the previous quarter. Cumulative sales this year were KRW 54.65 billion.

In the company's terms

Operating profit (profit from the core business) for the latest 3 months was KRW -1.31 billion. A year earlier it was KRW -1.06 billion. Cumulative operating profit this year was KRW -1.14 billion.

What changes for shareholders

Net income (the final profit after all costs and taxes) for the latest 3 months was KRW -2.89 billion. A year earlier it was KRW -4.68 billion. Cumulative net income this year was KRW -7.15 billion.

Comments

No comments yet

Comments from shareholders will appear here.